AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03238105
Drug: Thioglycolic Acid
RxNorm normalized name: Thioglycolic acid
DrugBank: Thioglycolic acid (DB15429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sessions for 3 months with progressive increase of the duration of contact time of the drug with the skin, 3, 6 and 9 minutes.
Trial: NCT00016666
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00866307
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT and IV or SC
Trial: NCT00866307
Drug: Daunorubicin Hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00866307
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01585792
Drug: TAK-875
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00866307
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00866307
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or PO
Trial: NCT00866307
Drug: Thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01585792
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00866307
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00028912
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00028912
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02468791
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00722150
Drug: Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 mg/kg/day x 7 days
Trial: NCT00722150
Drug: Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg/kg/day x 7 days
Trial: NCT00722150
Drug: Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 mg/kg/day x 7 days
Trial: NCT00671255
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
Trial: NCT00671255
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 8 mg, tablets, orally, once daily for up to 5 weeks.
Trial: NCT04963257
Drug: sertraline fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the initial dose of sertraline was given 50mg/d and the initial dose of fluvoxamine was 50mg/d, and the target dose of sertraline was gradually increased to 200mg/ d and the target dose of fluvoxamine was 200-300mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
Trial: NCT04963257
Drug: sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of sertraline was 50mg/d and the initial dose of aripiprazole was 5mg/d. The target dose of sertraline was 200mg/ d and the target dose of aripiprazole was 5-20mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
Trial: NCT04421495
Drug: Delamanid
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: the eligible patients will be give damanid-containing regimen
Trial: NCT00191594
Drug: Duloxetine Hydrochloride
RxNorm normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01902550
Drug: Metoprolol tartrate immediate-release (metoprolol IR)
RxNorm normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.
Trial: NCT01902550
Drug: JNJ-54452840
RxNorm normalized name: JNJ-54452840
DrugBank: Mibenratide (DB15195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
Trial: NCT01049763
Drug: oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
Trial: NCT04041882
Drug: 68Ga-DOTATATE
RxNorm normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-DOTATATE. Tracer doses of 68Ga-DOTATATE will be used to image lesions of NET PET/CT scan.
Trial: NCT01445262
Drug: Levocetirizine
RxNorm normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00603915
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m\^2 intravenous (IV) day 1 and day 8
Trial: NCT00603915
Drug: Carboplatin/Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Area under curve (AUC)=5 (Carboplatin) or 70mg/m\^2 (Cisplatin) intravenous (IV) day 1
Trial: NCT00603915
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg daily (post GC therapy)
Trial: NCT00705666
Drug: Ribavirin (SCH 18908)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
Trial: NCT01167829
Drug: Acyline
RxNorm normalized name: Acyline
DrugBank: Acyline (DB11906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ug/kg injection on Day 0
Trial: NCT03434977
Drug: TAK-536
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-536 granule formulation
Trial: NCT02055066
Drug: ARGX-111
RxNorm normalized name: ARGX-119
DrugBank: RGX-111 (DB17632)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00040755
Drug: rebimastat
RxNorm normalized name: Rebimastat
DrugBank: Rebimastat (DB06573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00506831
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
Trial: NCT02105415
Drug: Ketamine / Propofol Admixture
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02105415
Drug: Etomidate
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02439658
Drug: Dofetilide and/or sotalol
DrugBank: Dofetilide (DB00204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.
Trial: NCT00538720
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
Trial: NCT00476879
Drug: Somatropin and pegvisomant
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
Trial: NCT01545700
Drug: Dexamethasone 4 mg
RxNorm normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients randomized to receive dexamethasone 4mg and 1 cc saline
Trial: NCT01545700
Drug: Dexamethasone 8 mg
RxNorm normalized name: dexamethasone 8 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients randomized to receive dexamethasone 8mg
Trial: NCT01545700
Drug: Dexamethasone 4 mg
RxNorm normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are randomized to receive dexamethasone 4 mg and saline 1 cc
Trial: NCT01545700
Drug: Dexamethasone 8 mg
RxNorm normalized name: dexamethasone 8 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are randomized to receive dexamethasone 8 mg
Trial: NCT00291005
Drug: ARD6562, Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03861143
Drug: BT-11 (440 mg)
RxNorm normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily tablet
Trial: NCT03861143
Drug: BT-11 (880 mg)
RxNorm normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily tablet
Trial: NCT00281879
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
Trial: NCT00281879
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
Trial: NCT00281879
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
Trial: NCT00281879
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
Trial: NCT00281879
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.~Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload.
Trial: NCT00281879
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.~Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2.
Trial: NCT00281879
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
Trial: NCT00281879
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl-prednisolone is administered IV as a rapid infusion.
Trial: NCT00281879
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate may be used as a substitute for Methotrexate
Trial: NCT00281879
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A drug used to decrease the risk of graft versus host disease (GvHD).
Trial: NCT04763070
Drug: Ciprofloxacin Oral Product
RxNorm normalized name: ciprofloxacin Oral Product
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.
Trial: NCT01777581
Drug: Milnacipran
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00455598
Drug: ISIS 113715
RxNorm normalized name: ISIS 113715
DrugBank: ISIS 113715 (DB05506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doses of 100 and 200 mg per week
Trial: NCT02811692
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration by intravitreal injection
Trial: NCT01331356
Drug: Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: One injection of botulinum toxin type A in the ganglion Impar in patients with chronic proctalgia
Trial: NCT00616109
Drug: sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.
Trial: NCT04188184
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
Trial: NCT01972893
Drug: ZYD1
RxNorm normalized name: Zydelig
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Plan I - Tablet ZYD1 - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet ZYD1 - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet ZYD1 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I.
Trial: NCT00176280
Drug: Leukine
RxNorm normalized name: Leukine
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00176280
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03548051
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 ml of saline delivered by retention enema
Trial: NCT00590590
Drug: Lidocaine/Diphenhydramine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: semi solid, twice weekly, 4 months
Trial: NCT00590590
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: semi solid, twice weekly for 4 months
Trial: NCT02492503
Drug: Paclitaxel and carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
Trial: NCT02492503
Drug: Paclitaxel and carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
Trial: NCT00432978
Drug: Bosentan administration
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01826747
Drug: crinone (progesterone 8%, vaginal application)
RxNorm normalized name: Crinone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003385
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003385
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03215966
Drug: Macitentan (Opsumit®)
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Film-coated tablets for oral administration formulated at a strength of 10 mg
Trial: NCT03215966
Drug: Tadalafil (Adcirca®)
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablets for oral administration formulated at a strength of 20 mg
Trial: NCT00625092
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m\^2
Trial: NCT00807755
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.
Trial: NCT00807755
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.
Trial: NCT01863511
Drug: tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00356278
Drug: D-Cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
Trial: NCT00356278
Drug: Alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
Trial: NCT00316563
Drug: Marinol (Dronabinol)
RxNorm normalized name: dronabinol Oral Capsule [Marinol]
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
Trial: NCT01002963
Drug: PF-04418948
RxNorm normalized name: PF-04418948
DrugBank: PF-04418948 (DB12024)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, 30 mg, single
Trial: NCT01002963
Drug: PF-04418948
RxNorm normalized name: PF-04418948
DrugBank: PF-04418948 (DB12024)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, 100 mg, single
Trial: NCT01002963
Drug: PF-04418948
RxNorm normalized name: PF-04418948
DrugBank: PF-04418948 (DB12024)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, 300 mg, single
Trial: NCT01002963
Drug: PF-04418948
RxNorm normalized name: PF-04418948
DrugBank: PF-04418948 (DB12024)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, 1000 mg, single
Trial: NCT01002963
Drug: PF-04418948
RxNorm normalized name: PF-04418948
DrugBank: PF-04418948 (DB12024)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, 3000 mg, single
Trial: NCT02346760
Drug: UB-621
RxNorm normalized name: UB-612
DrugBank: UB-612 (DB16444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/ml, subcutaneous injection
Trial: NCT00647556
Drug: adapalene gel, 0.3%
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: applied topically once daily in the evening
Trial: NCT03365466
Drug: Low dose aspirin
RxNorm normalized name: Adult Low Dose Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LDA 25mg tid
Trial: NCT01002963
Drug: PF-04418948
RxNorm normalized name: PF-04418948
DrugBank: PF-04418948 (DB12024)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, 4500 mg, single
Trial: NCT01002963
Drug: PF-04418948
RxNorm normalized name: PF-04418948
DrugBank: PF-04418948 (DB12024)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, 6000 mg, single
Trial: NCT04200586
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.
Trial: NCT04342663
Drug: Fluvoxamine
RxNorm normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.